Tongji University School of Medicine, Shanghai, 200082, China.
Department of Cardiology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 of Zhouyuan Road, Pudong New District, Shanghai, 201318, China.
Mol Biotechnol. 2022 Jul;64(7):758-772. doi: 10.1007/s12033-022-00449-5. Epub 2022 Feb 2.
Atrial fibrillation (AF) is one of the most common arrhythmias in adults, with high morbidity and increased mortality risk. In recent years, the clinical diagnosis, treatment, and mechanistic research of AF have increased exponentially, and regulation based on the potential molecular mechanism of AF is a research hotspot. Long noncoding RNAs (LncRNAs), usually refer to noncoding RNA transcripts greater than 200 nucleotides in length, have been shown to play a role in cardiovascular diseases such as coronary artery disease, heart failure, and myocardial fibrosis through various regulatory methods. An increasing number of researchers have begun to pay attention to the identification and function of LncRNAs in AF. This article reviews changes in the expression of related LncRNAs detected in AF and describes the LncRNAs that play a regulatory role in AF-related processes, to explore the potential of LncRNAs as new biomarkers and therapeutic targets in AF.
心房颤动(AF)是成年人中最常见的心律失常之一,具有高发病率和增加的死亡风险。近年来,AF 的临床诊断、治疗和机制研究呈指数级增长,基于 AF 潜在分子机制的调控是一个研究热点。长链非编码 RNA(LncRNA)通常是指长度大于 200 个核苷酸的非编码 RNA 转录本,通过各种调节方式在冠状动脉疾病、心力衰竭和心肌纤维化等心血管疾病中发挥作用。越来越多的研究人员开始关注 AF 中相关 LncRNA 的鉴定和功能。本文综述了 AF 中检测到的相关 LncRNA 表达变化,并描述了在 AF 相关过程中发挥调节作用的 LncRNA,以探索 LncRNA 作为 AF 新的生物标志物和治疗靶点的潜力。